Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
13.49 -0.86 (-5.99%) 04/10/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 13.49 unch (unch) 16:01 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
13.18
Day High
14.56
Open 14.50
Previous Close 14.35 14.35
Volume 2,273,000 2,273,000
Avg Vol 1,942,515 1,942,515
Stochastic %K 9.77% 9.77%
Weighted Alpha +65.06 +65.06
5-Day Change -3.07 (-18.54%) -3.07 (-18.54%)
52-Week Range 5.12 - 25.29 5.12 - 25.29
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,273,878
  • Shares Outstanding, K 88,772
  • Annual Sales, $ 233,180 K
  • Annual Income, $ -321,550 K
  • EBIT $ -324 M
  • EBITDA $ -283 M
  • 60-Month Beta 0.84
  • Price/Sales 5.39
  • Price/Cash Flow N/A
  • Price/Book 18.69

Options Overview Details

View History
  • Implied Volatility 118.60% ( +35.65%)
  • Historical Volatility 68.33%
  • IV Percentile 90%
  • IV Rank 64.58%
  • IV High 171.71% on 08/16/24
  • IV Low 21.77% on 07/15/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 344
  • Volume Avg (30-Day) 394
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 28,668
  • Open Int (30-Day) 31,319

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.54
  • Number of Estimates 6
  • High Estimate -0.43
  • Low Estimate -0.68
  • Prior Year -1.76
  • Growth Rate Est. (year over year) +69.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.91 +4.49%
on 04/09/25
Period Open: 17.87
21.35 -36.81%
on 03/25/25
-4.38 (-24.51%)
since 03/10/25
3-Month
12.91 +4.49%
on 04/09/25
Period Open: 18.09
25.29 -46.66%
on 02/11/25
-4.60 (-25.43%)
since 01/10/25
52-Week
5.12 +163.48%
on 04/25/24
Period Open: 6.67
25.29 -46.66%
on 02/11/25
+6.82 (+102.25%)
since 04/10/24

Most Recent Stories

More News
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

TVTX : 13.49 (-5.99%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TVTX : 13.49 (-5.99%)
Travere Therapeutics to Participate at Upcoming Investor Conferences

TVTX : 13.49 (-5.99%)
Travere: Q4 Earnings Snapshot

Travere: Q4 Earnings Snapshot

TVTX : 13.49 (-5.99%)
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

TVTX : 13.49 (-5.99%)
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

TVTX : 13.49 (-5.99%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TVTX : 13.49 (-5.99%)
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

TVTX : 13.49 (-5.99%)
VTI : 257.43 (-4.12%)
IWM : 181.71 (-4.20%)
XBI : 71.61 (-4.37%)
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

TVTX : 13.49 (-5.99%)
Travere Therapeutics Provides Corporate Update and 2025 Outlook

TVTX : 13.49 (-5.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 15.69
2nd Resistance Point 15.12
1st Resistance Point 14.31
Last Price 13.49
1st Support Level 12.93
2nd Support Level 12.36
3rd Support Level 11.55

See More

52-Week High 25.29
Fibonacci 61.8% 17.59
Fibonacci 50% 15.20
Last Price 13.49
Fibonacci 38.2% 12.82
52-Week Low 5.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar